Like any medication, Dupixent may cause various side effects. It’s especially known to cause side effects relating to the eyes, such as conjunctivitis, blepharitis, and keratitis. These side effects ...

New findings from the EVEREST Phase 4 trial presented at the 2025 EAACI Congress reveal that Dupixent (dupilumab) significantly outperformed Xolair (omalizumab) in treating adults with severe chronic ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...